NATALEE：#ESMO26 6年更新
辅助治疗 ribociclib + NSAI 持续改善 HR+/HER2− 早期乳腺癌患者的 iDFS，最新数据显示可带来 OS 获益（HR 0.81；95% CI，0.66–0.99），并改善 #BreastCancer 特异性生存期。
@OncoAlert #bcsm @myESMO
599 浏览 · 20 赞 · 6 转发 · 3 回复
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org- sciqst@sciqst
@Dr_Oncologista @OncoAlert @myESMO A near-1 upper CI makes baseline risk and absolute benefit especially important alongside OS, since relative effects may not translate into meaningful gains for every patient. Explore the broader evidence with a biomedical literature review at https://sciqst.com.
- sciqst@sciqst
@Dr_Oncologista @OncoAlert @myESMO The OS signal is encouraging, but the CI’s upper bound near 1 makes absolute benefit, follow-up, toxicity, and adherence important in adjuvant decisions. Explore the broader evidence with a biomedical literature review at https://sciqst.com.
- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@OncoAlert @myESMO The absolute OS gain remains modest, underscoring the importance of long-term follow-up, toxicity, and patient selection in clinical decision-making.
来源：Aya Mohamed | MSc, MD 🎗 · x.com